WO2013035345A3 - Anticorps neutralisant les sérotypes du virus de la dengue - Google Patents

Anticorps neutralisant les sérotypes du virus de la dengue Download PDF

Info

Publication number
WO2013035345A3
WO2013035345A3 PCT/JP2012/005699 JP2012005699W WO2013035345A3 WO 2013035345 A3 WO2013035345 A3 WO 2013035345A3 JP 2012005699 W JP2012005699 W JP 2012005699W WO 2013035345 A3 WO2013035345 A3 WO 2013035345A3
Authority
WO
WIPO (PCT)
Prior art keywords
dengue
neutralizing antibodies
virus serotype
virus
serotype neutralizing
Prior art date
Application number
PCT/JP2012/005699
Other languages
English (en)
Other versions
WO2013035345A2 (fr
Inventor
Chayanee Setthapramote
Tadahiro Sasaki
Motoki Kuhara
Pongrama Ramasoota
Aree Thattiyaphong
Surapee Anantapreecha
Pathom Sawanpanyalert
Yoshinobu Okuno
Kazuyoshi Ikuta
Atchareeya A-nuegoonpipat
Panadda Dhepakson
Apichai Prachasuphap
Original Assignee
Osaka University
The Research Foundation For Microbial Diseases Of Osaka University
Medical And Biological Laboratories Co., Ltd
Mahidol University
Department of Medical Sciences (DMSc)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University, The Research Foundation For Microbial Diseases Of Osaka University, Medical And Biological Laboratories Co., Ltd, Mahidol University, Department of Medical Sciences (DMSc) filed Critical Osaka University
Priority to AU2012305807A priority Critical patent/AU2012305807B2/en
Priority to SG11201400100SA priority patent/SG11201400100SA/en
Publication of WO2013035345A2 publication Critical patent/WO2013035345A2/fr
Publication of WO2013035345A3 publication Critical patent/WO2013035345A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des matériaux et des méthodes permettant de traiter les infections par le virus de la dengue. L'invention concerne également des anticorps monoclonaux humains dirigés contre 11 sérotypes du virus de la dengue. L'invention concerne, par ailleurs, des méthodes consistant à utiliser des anticorps monoclonaux humains afin de neutraliser tous les sérotypes du virus de la dengue, lesdites méthodes faisant appel aux lymphocytes du sang périphérique des patients.
PCT/JP2012/005699 2011-09-09 2012-09-07 Anticorps neutralisant les sérotypes du virus de la dengue WO2013035345A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2012305807A AU2012305807B2 (en) 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies
SG11201400100SA SG11201400100SA (en) 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161532671P 2011-09-09 2011-09-09
US201161532605P 2011-09-09 2011-09-09
US61/532,671 2011-09-09
US61/532,605 2011-09-09

Publications (2)

Publication Number Publication Date
WO2013035345A2 WO2013035345A2 (fr) 2013-03-14
WO2013035345A3 true WO2013035345A3 (fr) 2013-09-06

Family

ID=47116163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/005699 WO2013035345A2 (fr) 2011-09-09 2012-09-07 Anticorps neutralisant les sérotypes du virus de la dengue

Country Status (4)

Country Link
AU (1) AU2012305807B2 (fr)
MY (1) MY170725A (fr)
SG (1) SG11201400100SA (fr)
WO (1) WO2013035345A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3105249B1 (fr) 2014-02-11 2021-09-15 Visterra, Inc. Molécules d'anticorps se liant au virus de la dengue et leurs utilisations
CN105004860B (zh) * 2015-07-24 2016-09-21 鲁东大学 氟苯尼考快速检测试剂盒及其制备、使用方法
CN105137068B (zh) * 2015-07-24 2017-03-01 鲁东大学 氟苯尼考现场检测试纸及其制备、使用方法
AU2017238651B2 (en) 2016-03-25 2024-06-13 Visterra, Inc. Formulation of antibody molecules to dengue virus
CN109929033B (zh) * 2019-03-15 2020-06-02 中国人民解放军军事科学院军事医学研究院 一种特异性结合四种血清型登革病毒的人源抗体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076677A2 (fr) * 2003-02-26 2004-09-10 Institute For Research In Biomedicine Production d'anticorps monoclonaux par transformation de lymphocytes b par le virus d'epstein barr
EP2009094A1 (fr) * 2006-04-13 2008-12-31 Medical and Biological Laboratories Co., Ltd. Cellules partenaires de fusion
WO2009011941A2 (fr) * 2007-04-04 2009-01-22 The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services Anticorps monoclonaux contre le virus de la dengue et d'autres virus avec délétion dans la région fc
WO2010043977A2 (fr) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Anticorps de neutralisation du virus de la dengue et leurs utilisations
WO2010073647A1 (fr) * 2008-12-25 2010-07-01 国立大学法人大阪大学 Anticorps humain anti-virus de la grippe humaine
WO2010093335A1 (fr) * 2009-02-10 2010-08-19 Nanyang Technological University Anticorps destinés au diagnostic et au traitement d'infections flavivirales

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
AU8755798A (en) 1997-04-04 1998-11-13 Biosite Diagnostics Incorporated Polyvalent and polyclonal libraries

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076677A2 (fr) * 2003-02-26 2004-09-10 Institute For Research In Biomedicine Production d'anticorps monoclonaux par transformation de lymphocytes b par le virus d'epstein barr
EP2009094A1 (fr) * 2006-04-13 2008-12-31 Medical and Biological Laboratories Co., Ltd. Cellules partenaires de fusion
WO2009011941A2 (fr) * 2007-04-04 2009-01-22 The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services Anticorps monoclonaux contre le virus de la dengue et d'autres virus avec délétion dans la région fc
WO2010043977A2 (fr) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Anticorps de neutralisation du virus de la dengue et leurs utilisations
WO2010073647A1 (fr) * 2008-12-25 2010-07-01 国立大学法人大阪大学 Anticorps humain anti-virus de la grippe humaine
WO2010093335A1 (fr) * 2009-02-10 2010-08-19 Nanyang Technological University Anticorps destinés au diagnostic et au traitement d'infections flavivirales

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. K. I. FALCONAR: "Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins", ARCHIVES OF VIROLOGY, vol. 144, no. 12, 16 December 1999 (1999-12-16), pages 2313 - 2330, XP055052767, ISSN: 0304-8608, DOI: 10.1007/s007050050646 *
CHAYANEE SETTHAPRAMOTE ET AL: "Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 423, no. 4, 13 July 2012 (2012-07-13), pages 867 - 872, XP028427449, ISSN: 0006-291X, [retrieved on 20120617], DOI: 10.1016/J.BBRC.2012.06.057 *
KUBOTA-KOKETSU R ET AL: "Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 387, no. 1, 11 September 2009 (2009-09-11), pages 180 - 185, XP026378974, ISSN: 0006-291X, [retrieved on 20090704], DOI: 10.1016/J.BBRC.2009.06.151 *

Also Published As

Publication number Publication date
AU2012305807A8 (en) 2014-03-13
SG11201400100SA (en) 2014-06-27
WO2013035345A2 (fr) 2013-03-14
AU2012305807A1 (en) 2014-02-20
AU2012305807B2 (en) 2015-08-20
MY170725A (en) 2019-08-27

Similar Documents

Publication Publication Date Title
PH12016500859A1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
PH12017501075B1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MX2012001882A (es) Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
PH12015501558A1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
EA201300016A1 (ru) Конъюгаты антител человека против тканевого фактора с лекарственными препаратами
EA201400855A1 (ru) Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
WO2013035345A3 (fr) Anticorps neutralisant les sérotypes du virus de la dengue
WO2012006500A3 (fr) Anticorps monoclonaux contre la protéine de capside du virus de l'hépatite c
MX356745B (es) Anticuerpo monoclonal humano contra la proteina vp1 del virus jc.
WO2012110968A3 (fr) Traitement de la maladie de crohn à fistules
WO2012119989A3 (fr) Procédés et anticorps pour le diagnostic et le traitement du cancer
WO2012149525A3 (fr) Vaccin et anticorps pour ureaplasma pour prévenir et traiter une infection d'un être humain, d'un animal et d'une culture cellulaire
TH141036A (th) แอนติบอดีชนิดลบล้างฤทธิ์จำเพาะต่อเซโรทัยป์ของไวรัสเดงกี (dengue-virus serotype neutralizing antibodies)
TH156774A (th) โมโนโคลนอลแอนติบอดี้ของมนุษย์ ที่มีความจำเพาะสำหรับโปรตีนของไวรัสเด็งกี่ ซีไรไทป์1 e และการใช้ของสารเหล่านี้ (human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof)
WO2012112842A3 (fr) Compositions et procédés pour traiter le poliovirus
HK1211298A1 (en) Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection n-(pnag) pnag
EA201992775A2 (ru) Конъюгаты антител человека против тканевого фактора с лекарственными препаратами

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12780548

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2012305807

Country of ref document: AU

Date of ref document: 20120907

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12014500544

Country of ref document: PH

122 Ep: pct application non-entry in european phase

Ref document number: 12780548

Country of ref document: EP

Kind code of ref document: A2